Making the next steps in psoriatic arthritis management: current status and future directions

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Therapeutic Advances in Musculoskeletal Disease

• Publication date

  2015-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1177/1759720X15595966PMID 26425146PMCID PMC4572364
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• MEASURING DISEASE ACTIVITY IN PSORIATIC ARTHRITIS

  2017cited by this paper
• Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)

  2016cited by this paper
• [Cardiovascular risk in patients with psoriatic arthritis].

  2016cited by this paper
• The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis

  2015cited by this paper
• OP0174 Efficacy and Safety of Ustekinumab in Psoriatic Arthritis Patients with Spondylitis and Peripheral Joint Involvement: Results from a Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study

  2015cited by this paper
• Updated Guidelines for the Management of Axial Disease in Psoriatic Arthritis

  2014cited by this paper
• The risks and benefits of glucocorticoid treatment for tendinopathy: a systematic review of the effects of local glucocorticoid on tendon.

  2014cited by this paper
• Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials

  2014cited by this paper
• Predictors of functional deterioration in Chinese patients with Psoriatic arthritis: a longitudinal study

  2014cited by this paper
• Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled,

  2014cited by this paper
• 212. Long-Term 52-Week Results of Palace 3, A Phase 3, Randomized, Controlled Trial of Apremilast, An Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis and Current Skin Involvement

  2014cited by this paper
• Comprehensive Treatment of Psoriatic Arthritis: Managing Comorbidities and Extraarticular Manifestations

  2014cited by this paper
• A review of disease activity measures for psoriatic arthritis: what is the best approach?

  2014cited by this paper
• Systematic Review of Treatment Effectiveness and Outcome Measures for Enthesitis in Psoriatic Arthritis

  2014cited by this paper
• A Systematic Literature Review on the Application of Rasch Analysis in Musculoskeletal Disease — A Special Interest Group Report of OMERACT 11

  2014cited by this paper
• Safety and Efficacy of Therapies for Skin Symptoms of Psoriasis in Patients with Psoriatic Arthritis: A Systematic Review

  2014cited by this paper
• Atherosclerosis progression in psoriatic arthritis patients despite the treatment with tumor necrosis factor-alpha blockers: a two-year prospective observational study.

  2014cited by this paper
• A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative

  2014cited by this paper
• Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor

  2014cited by this paper
• Comprehensive Treatment of Dactylitis in Psoriatic Arthritis

  2014cited by this paper
• Drug Therapies for Peripheral Joint Disease in Psoriatic Arthritis: A Systematic Review

  2014cited by this paper
• Development of a Disease Activity and Responder Index for Psoriatic Arthritis — Report of the Psoriatic Arthritis Module at OMERACT 11

  2014cited by this paper
• Chronic Plaque Psoriasis and Metabolic Syndrome

  2013cited by this paper
• The TICOPA protocol (TIght COntrol of Psoriatic Arthritis): a randomised controlled trial to compare intensive management versus standard care in early psoriatic arthritis

  2013cited by this paper
• Efficacy and safety of secukinumab in the treatment of moderate‐to‐severe plaque psoriasis: a randomized, double‐blind, placebo‐controlled phase II dose‐ranging study

  2013cited by this paper
• Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial

  2013cited by this paper
• Effect of tumour necrosis factor blockers on radiographic progression of psoriatic arthritis: a systematic review and meta-analysis of randomised controlled trials

  2013cited by this paper
• Direct and indirect comparison of the efficacy and safety of adalimumab, etanercept, infliximab and golimumab in psoriatic arthritis

  2013cited by this paper
• Risk of Non‐Hodgkin's Lymphoma in Primary Sjögren's Syndrome: A Population‐Based Study

  2013cited by this paper
• Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial.

  2013cited by this paper
• Disease assessment in psoriatic spectrum: a modular approach for use in routine clinical practice

  2013cited by this paper
• Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)

  2013cited by this paper
• Leflunomide in psoriatic arthritis: Results from a large European prospective observational study

  2013cited by this paper
• Sensitivity and specificity of the classification of psoriatic arthritis criteria in early psoriatic arthritis.

  2012cited by this paper
• Recommendations for the treatment of nail psoriasis in patients with moderate to severe psoriasis: a dermatology expert group consensus

  2012cited by this paper
• Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review

  2012cited by this paper
• Cardiovascular Risk in Patients with Psoriatic Arthritis

  2012cited by this paper
• Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial.

  2012cited by this paper
• Measuring Disease Activity in Psoriatic Arthritis

  2012cited by this paper
• A randomized placebo-controlled trial of methotrexate in psoriatic arthritis

  2012cited by this paper
• Clinical outcomes in psoriatic arthritis: A systematic literature review

  2012cited by this paper
• Performance of classification criteria for peripheral spondyloarthritis and psoriatic arthritis in the Leiden early arthritis cohort

  2012cited by this paper
• Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis.

  2012cited by this paper
• Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)

  2012cited by this paper
• Anti-tumor necrosis factor (TNF) drugs for the treatment of psoriatic arthritis: an indirect comparison meta-analysis

  2012cited by this paper
• IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4−CD8− entheseal resident T cells

  2012cited by this paper
• Consensus guidelines for the management of plaque psoriasis.

  2012cited by this paper
• Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis.

  2012cited by this paper
• Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study

  2012cited by this paper
• High prevalence of psoriatic arthritis in patients with severe psoriasis with suboptimal performance of screening questionnaires

  2012cited by this paper
• European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies

  2011cited by this paper
• Safety of non-steroidal anti-inflammatory drugs, including aspirin and paracetamol (acetaminophen) in people receiving methotrexate for inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis).

  2011cited by this paper
• Evaluation of spinal mobility measurements in predicting axial psoriatic arthritis

  2011cited by this paper
• A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis

  2011cited by this paper
• Carotid Intima-Media Thickness in Psoriatic Arthritis: Differences Between Tumor Necrosis Factor-&agr; Blockers and Traditional Disease-Modifying Antirheumatic Drugs

  2011cited by this paper
• Cardiovascular and other comorbidities in patients with psoriatic arthritis: A comparison with patients with psoriasis

  2011cited by this paper
• Observational cohort studies: lessons learnt from the University of Toronto Psoriatic Arthritis Program.

  2011cited by this paper
• Atherosclerosis in psoriatic arthritis.

  2011cited by this paper
• 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis

  2011cited by this paper
• Differential Features Between Primary Ankylosing Spondylitis and Spondylitis Associated with Psoriasis and Inflammatory Bowel Disease

  2011cited by this paper
• Evaluation of the CASPAR criteria for psoriatic arthritis in the Chinese population.

  2010cited by this paper
• Tumour necrosis factor alpha blockade is associated with sustained regression of carotid intima-media thickness for patients with active psoriatic arthritis: a 2-year pilot study

  2010influential reference
• Use of methotrexate in patients with psoriatic arthritis.

  2010cited by this paper
• Obesity in early adulthood as a risk factor for psoriatic arthritis.

  2010cited by this paper
• Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data

  2010cited by this paper
• Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs

  2010cited by this paper
• Predictors of response to intra-articular steroid injection in psoriatic arthritis.

  2010cited by this paper
• Socioeconomic Burden of Psoriatic Arthritis in Hong Kong: Direct and Indirect Costs and the Influence of Disease Pattern

  2010cited by this paper
• Generalized pustular psoriasis induced by systemic glucocorticosteroids: four cases and recommendations for treatment

  2009cited by this paper
• Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment

  2009cited by this paper
• EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis

  2009cited by this paper
• Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide

  2009cited by this paper
• Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study.

  2009cited by this paper
• Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study.

  2009cited by this paper
• Impact of illness and variables associated with functional impairment in Chinese patients with psoriatic arthritis.

  2008cited by this paper
• The effectiveness of a traditional therapeutical approach in early psoriatic arthritis: results of a pilot randomised 6-month trial with methotrexate

  2008cited by this paper
• Treatment recommendations for psoriatic arthritis

  2008cited by this paper
• Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT)

  2008cited by this paper
• Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis.

  2008cited by this paper
• A systematic review and meta-analysis of efficacy and toxicity of disease modifying anti-rheumatic drugs and biological agents for psoriatic arthritis

  2007cited by this paper
• Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial.

  2007cited by this paper
• Sensitivity of the classification of psoriatic arthritis criteria in early psoriatic arthritis.

  2007cited by this paper
• Consensus on a core set of domains for psoriatic arthritis.

  2007cited by this paper
• A comparison of the efficacy and safety of celecoxib 200 mg and celecoxib 400 mg once daily in treating the signs and symptoms of psoriatic arthritis.

  2007cited by this paper
• Metabolic disorders in patients with psoriasis and psoriatic arthritis

  2006cited by this paper
• Classification criteria for psoriatic arthritis: development of new criteria from a large international study.

  2006cited by this paper
• The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year

  2006cited by this paper
• Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial

  2006cited by this paper
• Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept.

  2006cited by this paper
• Healthcare and burden of disease in psoriatic arthritis. A comparison with rheumatoid arthritis and ankylosing spondylitis.

  2006cited by this paper
• Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial

  2005cited by this paper
• Psoriatic arthritis assessment tools in clinical trials

  2005cited by this paper
• Classification and diagnostic criteria for psoriatic arthritis

  2005cited by this paper
• Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial.

  2005cited by this paper
• Development of the PsAQoL: a quality of life instrument specific to psoriatic arthritis

  2004cited by this paper
• Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression.

  2004cited by this paper
• Randomized, placebo-controlled trial

  2004cited by this paper
• Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial.

  2004cited by this paper
• The anatomical basis for disease localisation in seronegative spondyloarthropathy at entheses and related sites

  2001cited by this paper
• Health-related quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis.

  2001cited by this paper

• Coccidiomycosis septic arthritis presenting as ankle monoarthritis in a patient with presumed psoriatic arthritis

  2024cites this paper
• Upadacitinib effectiveness and factors associated with minimal disease activity achievement in patients with psoriatic arthritis: preliminary data of a real-life multicenter study

  2023cites this paper
• Atypical Psoriatic Arthritis Presenting as Presumed Septic Monoarticular Arthritis

  2020cites this paper
• Choosing the right treatment for patients with psoriatic arthritis

  2020cites this paper
• Treatment Patterns with Disease-Modifying Antirheumatic Drugs in U.S. Veterans with Newly Diagnosed Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis.

  2019cites this paper
• Dynamics of Carotid Intima-Media Thickness, Parameters of Arterial Stiffness and Ambulatory Blood Pressure Monitoring during Therapy with Inhibitor of Tumor Necrosis Factor-Alpha in Patients with Early Psoriatic Arthritis

  2018cites this paper
• Management of youth psoriatic arthritis with etanercept: a case report

  2018cites this paper
• Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison.

  2018cites this paper
• Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison

  2018cites this paper
• Role and Function of A2A and A3 Adenosine Receptors in Patients with Ankylosing Spondylitis, Psoriatic Arthritis and Rheumatoid Arthritis

  2017cites this paper
• Protocolo diagnóstico de la dactilitis

  2017cites this paper
• Improved clinical, functional and work outcomes in spondyloarthritides during real-life adalimumab treatment in central-eastern Europe.

  2016cites this paper